Steroids: Pharmacology, complications, and practice Delivery Issues

Ochsner Journal

Volumn 14, Issue 2, 2014, Pages 203-207

  Ericson Neilsen, William ^a   Kaye, Alan David ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenal cortex hormones; Diabetes mellitus; Drugrelated side effects and adverse reactions; Glucocorticoids; Medication therapy management; Mineralocorticoids

Indexed keywords

BETAMETHASONE; BETAMETHASONE SODIUM PHOSPHATE; CORTICOSTEROID; DEXAMETHASONE; FLUDROCORTISONE; GLUCOCORTICOID; METHYLPREDNISOLONE; MINERALOCORTICOID; STEROID; TRIAMCINOLONE;

ADRENAL SUPPRESSION; ADVERSE OUTCOME; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; ARTICLE; BODY WEIGHT DISORDER; BONE MINERALIZATION; CATARACT; CUSHING SYNDROME; DELIRIUM; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG USE; GINGIVA DISEASE; HUMAN; HYPOPITUITARISM; INSULIN RESISTANCE; MOOD DISORDER; MUSCLE WEAKNESS; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PANIC; PATHOLOGIC FRACTURE; POTASSIUM DEFICIENCY; POTASSIUM EXCRETION; PRACTICE GUIDELINE; SKIN BRUISING; SKIN DISEASE; SLEEP DISORDER; SODIUM RETENTION; THRUSH; WATER RETENTION;

EID: 84902115101     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kendall, EC. Nobel lecture: The development of cortisone as a therapeutic agent. Nobelprize.org. December 11, 1950. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1950/kendall-lecture.html. Accessed March 10, 2013.
2. Stewart PM, Krone NP. The adrenal cortex. In: Melmed S, Polonsky K, Larsen PR, Kronenberg H, eds. Williams Textbook of Endocrinology. 12th ed. Philadelphia, PA: Saunders; 2011.
3. Xu J, Winkler J, Derendorf H. A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma. J Pharmacokinet Pharmacodyn. 2007 Jun;34(3):355-372. Epub 2007 Feb 23.
4. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006 Jun 15;55(3):420-426.
5. Kenna HA, Poon AW, de los Angeles CP, Koran LM. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011 Oct;65(6):549-560.
6. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006 Oct;81(10):1361-1367.
7. Patten SB, Neutel CI. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. Drug Saf. 2000 Feb;22(2):111-122.
8. Pereira RM, Carvalho JF, Canalis E. Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics (Sao Paulo). 2010; 65(11):1197-1205.
9. Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med. 2011 Nov;78(11):748-756.
10. Benzon HT, Gissen AJ, Strichartz GR, Avram MJ, Covino BG. The effect of polyethylene glycol on mammalian nerve impulses. Anesth Analg. 1987 Jun;66(6):553-559.
11. Craig DB, Habib GG. Flaccid paraparesis following obstetrical epidural anesthesia: possible role of benzyl alcohol. Anesth Analg. 1977 Mar-Apr;56(2):219-221.
12. Ahadian FM, McGreevy K, Schulteis G. Lumbar transforaminal epidural dexamethasone: a prospective, randomized, doubleblind, dose-response trial. Reg Anesth Pain Med. 2011 Nov-Dec; 36(6):572-578.
13. Dreyfuss P, Baker R, Bogduk N. Comparative effectiveness of cervical transforaminal injections with particulate and nonparticulate corticosteroid preparations for cervical radicular pain. Pain Med. 2006 May-Jun;7(3):237-242.
14. Somayaji HS, Saifuddin A, Casey AT, Briggs TW. Spinal cord infarction following therapeutic computed tomography-guided left L2 nerve root injection. Spine (Phila Pa 1976). 2005 Feb 15; 30(4):E106-E108.
15. McClain RW, Yentzer BA, Feldman SR. Comparison of skin concentrations following topical versus oral corticosteroid treatment: reconsidering the treatment of common inflammatory dermatoses. J Drugs Dermatol. 2009 Dec;8(12): 1076-1079.
16. Morley KW, Dinulos JG. Update on topical glucocorticoid use in children. Curr Opin Pediatr. 2012 Feb;24(1):121-128.
17. Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012 Jan;67(1): 35-41. Epub 2011 Aug 9.
18. Doherty DE, Tashkin DP, Kerwin E, et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:57-71. Epub 2012 Feb 3.
19. Taplin CE, Cowell CT, Silink M, Ambler GR. Fludrocortisone therapy in cerebral salt wasting. Pediatrics. 2006 Dec;118(6): e1904-e1908.
20. Freitas J, Santos R, Azevedo E, Costa O, Carvalho M, de Freitas AF. Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res. 2000 Oct;10(5):293-299.
21. Physicians Total Care, Inc. Fludrocortisone acetate tablet. Daily Med. September 2010. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid1/4bf927cd9-1891-4de4-b4be-743a26363a64. Accessed April 1, 2014.
22. Wallner BP, Mattaliano RJ, Hession C, et al. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature. 1986 Mar 6-12; 320(6057):77-81.
23. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med. 2005 Oct 20;353(16):1711-1723.
24. Blackwell GJ, Carnuccio R, Di Rosa M, Flower RJ, Parente L, Persico P. Macrocortin: a polypeptide causing the antiphospholipase effect of glucocorticoids. Nature. 1980 Sep 11; 287(5778):147-149.
25. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003 Feb 20;348(8):727-734.
26. Centers for Disease Control and Prevention. Multistate outbreak of fungal meningitis and other infections. Centers for Disease Control and Prevention. October 23, 2013. http://www.cdc.gov/hai/outbreaks/meningitis.html. Accessed April 1, 2014.
27. US Food and Drug Administration. 2006 Limited Survey of Compounded Drug Products. March 22, 2010. http://www.fda. gov/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/ucm204237.htm. Accessed March 14, 2013.
28. US Food and Drug Administration. FDA Form 483: inspectional observations. 2012. http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/UCM325980.pdf. Accessed March 14, 2013.
29. US Food and Drug Administration. Compounding Quality Act, Title I of the Drug Quality and Security Act of 2013. January 10, 2014. http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/default.htm. Accessed April 1, 2014.